Breakthroughs in research for pancreatic cancers, colon cancers, urologic cancers, melanoma, and breast cancers have uncovered markers, genes, and protein patterns which offer substantial insights into screening methods, cancers before they develop, and recurrence prevention. “So, all these strategies woven together form a multifaceted attack on cancer that’s going to have major impact in the future,” remarks Dr. Neil Martin, Medical Director of Saint John’s Cancer Institute and world-renowned neurosurgeon.<\/p>\n
Patient-focused clinical trials are leading the fight in treating cancers as well. These are studies conducted by a team of dedicated physicians, researchers and scientists to find immediate results during a trial versus waiting for results after a trial has ended. Saint John’s Cancer Institute and Saint John’s Health Center have this unique ability to assess in the lab and then treat in the clinic as is physiologically appropriate to an individual’s biology. What these patient-focused trials are providing are increased pathways of relational data during a trial. “So, it really distinguishes us as this relatively small institution with the power to leverage not only the engagement of our patients, the strength of our research, but our ability to move the dial and be able to find answers that everyone is looking for,” explains Dr. Gordon.<\/p>\n “We can set a precedence for the rest of the world on how clinical studies should be used to benefit patients in real-time and not 10 years after all the data has been aggregated in some way,” says Dr. Nicholas Schork, a quantitative data scientist who is considered to be by his peers, ‘the godfather’ of data science, and adjunct faculty at Saint John’s Cancer Institute. <\/p>\n![\"Dr.](\"https:\/\/www.saintjohnscancer.org\/blog\/wp-content\/uploads\/sites\/11\/2023\/11\/Dr-Ora-Gordon-presents.jpg\")
Event Preview: Researchers, Clinicians, and Scientists Discuss the End of Cancer<\/h3>\n